Onkologie. 2013:7(5):246-248
Novel predictive biomarker RAS: a crossroads or continuing the path taken?
- Biomedicínské centrum, Lékařská fakulta v Plzni, Univerzita Karlova v Praze, Plzeň
- Onkologické a radioterapeutické oddělení, Fakultní nemocnice Plzeň
- Chirurgická klinika Fakultní nemocnice Plzeň
Colorectal cancer has the highest incidence rate in the Czech Republic and occupies one of the leading positions in incidence worldwide.
Only patients with resectable distant metastases have hope for a cure. Prolongation of survival and improvement in the quality of life
thus remain the main goal of cancer treatment. The possibilities of classic chemotherapy appear to be currently exhausted. Further
prolongation of survival of patients with metastatic colorectal cancer (mCRC) has been provided by targeted biological therapy. It is
crucial to find suitable predictive biomarkers that will allow identification of a target population of patients. The review article analyses
the RAS mutation status with respect to the possible sequence of targeted biological therapy in patients with mCRC.
Keywords: colorectal cancer, sequence of targeted therapy, RAS
Published: November 1, 2013 Show citation
References
- http://www.cba.muni.cz/svod.
- Schmoll HJ, Van Cutsem E, Stein A, et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol 2012; 23: 2479-2516.
Go to original source... 
Go to PubMed... - Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342. Go to original source... Go to PubMed...
- Van Cutsem E, Kohne CH, Lang I, et al. Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status. J Clin Oncol 2011; 29: 2011-2019. Go to original source... Go to PubMed...
- Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010; 28: 4697-4705. Go to original source... Go to PubMed...
- Douillard JY, Siena S, Tabernero J, et al. Overall survival (OS) analysis from PRIME: randomized phase 3 study of panitumumab (pmab) with FOLFOX4 for 1st line metastatic colorectal cancer (mCRC). ASCO 2013 (poster): 3620. Go to original source...
- Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26: 1626-1634. Go to original source... Go to PubMed...
- Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757-1765. Go to original source... Go to PubMed...
- Oliner K, Douillard JY, Siena S, et al. Analysis of KRAS/NRAS and BRAF mutations in the phase III PRIME study of panitumumab (pmab) plus FOLFOX versus FOLFOX as first-line treatment (tx) for metastatic colorectal cancer (mCRC). ASCO 2013 (poster discussion): 3511. Go to original source...
- Schwartzberg L, Rivera F, Karthaus M, et al. Analysis of KRAS/NRAS mutations in PEAK: A randomized phase II study of FOLFOX6 plus panitumumab (pmab) or bevacizumab (bev) as first-line treatment (tx) for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRCJ Clin Oncol 31, 2013 (suppl; abstr 3631). Go to original source...
- Schwartzberg LS, Rivera F, Karthaus M, et al. PEAK (study 20070509): A randomized phase II study of mFOLFOX6 with either panitumumab (pmab) or bevacizumab (bev) as first-line treatment (tx) in patients (pts) with unresectable wild-type (WT) KRAS metastatic colorectal cancer (mCRC). J Clin Oncol 2013; 30(Suppl 34): 446. Go to original source...
- Heinemann V, et al. Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS wild-type metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3). ASCO 2013 (Abstract No. LBA3506). Go to original source...
- Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25: 1539-1544. Go to original source... Go to PubMed...
- Arnold D, Andre T, Bennouna J, et al. Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: Results of a randomized phase III intergroup study (TML study). J Clin Oncol 2012; 30(Suppl): CRA3503. Go to original source... Go to PubMed...
- Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of Aflibercept to Fluorouracil, Leucovorin, and Irinotecan Improves Survival in a Phase III Randomized Trial in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin-Based Regimen. J Clin Oncol 2012; 30: 3499-506. Go to original source... Go to PubMed...
- http://www.linkos.cz/informace-pro-praxi/modra-kniha/.